Click here for
An in vitro assay in which epinastine showed low to no binding affinity to muscarinic receptors4

The clinical significance of the in vitro data is unknown.


Click here for
Effect of topical ophthalmic epinastine on tear volume in mice

This new study in mice demonstrated ELESTAT® does not exacerbate ocular surface drying11


Click here for
An evaluation of the ocular drying effects of a systemic antihistamine compared to a topical antihistamine in patients with seasonal allergic conjunctivitis
This new study about the ocular surface after ELESTAT® treatment showed4:
  • No change in corneal staining
  • No change in tear volume
  • No change in tear-film break-up time

 

 
Controls the itch to soothe the eyes . . . without exacerbating ocular drying4


Click here for references




©2006 Inspire Pharmaceuticals, Inc., Durham, NC 27703 ® Marks owned by Allergan, Inc. Inspire and the Inspire logo are registered trademarks of Inspire Pharmaceuticals, Inc. ELESTAT® is licensed from Boehringer Ingelheim Pty. Ltd., Ingelheim, Germany.


ELESTAT® ophthalmic solution is indicated for the prevention of ocular itching associated with allergic conjunctivitis.

Important Safety Information:
ELESTAT® ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to epinastine or to any of the other ingredients.

Patients should be advised not to wear a contact lens if their eye is red. ELESTAT® ophthalmic solution should not be used to treat contact lens related irritation. The preservative in ELESTAT®, benzalkonium chloride, may be absorbed by soft contact lenses.Contact lenses should be removed prior to instillation of ELESTAT® ophthalmic solution and may be reinserted after 10 minutes following its administration.

The most frequently reported ocular adverse events occuring in approximately 1% to 10% of patients were burning sensation in the eye, folliculosis, hyperemia, and pruritus. The most frequently reported nonocular adverse events were infection (cold symptoms and upper respiratory infections), seen in approximately 10% of patients, and headache, rhinitis, sinusitis, increased cough, and pharyngitis seen in approximately 1% to 3% of patients. Some of these events were similar to the underlying disease being studied.

Please see prescribing information for ELESTAT®.